Search Results - "Becerra, Carlos R"

Anti-inflammatory Triterpenoid Blocks Immune Suppressive Function of MDSCs and Improves Immune Response in Cancer by NAGARAJ, Srinivas, YOUN, Je-In, SPORN, Michael B, LIBY, Karen T, RAWAL, Bhupendra, LEE, Ji-Hyun, GABRILOVICH, Dmitry I, WEBER, Hannah, ICLOZAN, Cristina, LU, Lily, COTTER, Matthew J, MEYER, Colin, BECERRA, Carlos R, FISHMAN, Mayer, ANTONIA, Scott

“…Myeloid-derived suppressor cells (MDSC) are one of the major factors responsible for immune suppression in cancer. Therefore, it would be important to identify…”
Get full text

Phase 1 study of MRX34, a liposomal miR-34a mimic, in patients with advanced solid tumours by Hong, David S., Kang, Yoon-Koo, Borad, Mitesh, Sachdev, Jasgit, Ejadi, Samuel, Lim, Ho Yeong, Brenner, Andrew J., Park, Keunchil, Lee, Jae-Lyun, Kim, Tae-You, Shin, Sangjoon, Becerra, Carlos R., Falchook, Gerald, Stoudemire, Jay, Martin, Desiree, Kelnar, Kevin, Peltier, Heidi, Bonato, Vinicius, Bader, Andreas G., Smith, Susan, Kim, Sinil, O’Neill, Vincent, Beg, Muhammad S.

“…Background In this first-in-human, Phase 1 study of a microRNA-based cancer therapy, the recommended Phase 2 dose (RP2D) of MRX34, a liposomal mimic of…”
Get full text

Enhanced Chemosensitivity to Irinotecan by RNA Interference-Mediated Down-Regulation of the Nuclear Factor-κB p65 Subunit by JUN GUO, VERMA, Udit N, GAYNOR, Richard B, FRENKEL, Eugene P, BECERRA, Carlos R

“…In preclinical tumor models, inhibition of nuclear factor-κB (NF-κB) has been associated with increased sensitivity to chemotherapeutic agents such as…”
Get full text

Phase I study of the MEK inhibitor trametinib in combination with the AKT inhibitor afuresertib in patients with solid tumors and multiple myeloma by Tolcher, Anthony W., Patnaik, Amita, Papadopoulos, Kyriakos P., Rasco, Drew W., Becerra, Carlos R., Allred, Alicia J., Orford, Keith, Aktan, Gursel, Ferron-Brady, Geraldine, Ibrahim, Nageatte, Gauvin, Jennifer, Motwani, Monica, Cornfeld, Mark

“…Purpose To identify the maximum tolerated dose (MTD) and recommended Phase II dose of MEK/AKT inhibitor combination of trametinib and afuresertib. Patients and…”
Get full text

Patient-reported Symptoms of Tenosynovial Giant Cell Tumors by Gelhorn, Heather L., PhD, Tong, Sandra, MD, McQuarrie, Kelly, BS, Vernon, Christina, MPH, Hanlon, Jennifer, MPH, Maclaine, Grant, BMedSc, MBBS, MEc, MA, Lenderking, William, PhD, Ye, Xin, PhD, MS, Speck, Rebecca M., PhD, MPH, Lackman, Richard D., MD, Bukata, Susan V., MD, Healey, John H., MD, Keedy, Vicki L., MD, MSCI, Anthony, Stephen P., DO, Wagner, Andrew J., MD, PhD, Von Hoff, Daniel D., MD, Singh, Arun S., MD, Becerra, Carlos R., MD, Hsu, Henry H., MD, Lin, Paul S., MD, MBA, Tap, William D., MD

“…Abstract Purpose Tenosynovial giant cell tumor (TGCT), a rare locally aggressive neoplasm of the synovium of joints and tendon sheaths, is associated with…”
Get full text

A phase I, open-label study evaluating the safety and pharmacokinetics of trifluridine/tipiracil in patients with advanced solid tumors and varying degrees of renal impairment by Saif, Muhammad Wasif, Becerra, Carlos R., Fakih, Marwan G., Sun, Weijing, Popovic, Lazar, Krishnamurthi, Smitha, George, Thomas J., Rudek, Michelle A., Shepard, Dale R., Skopek, Jiri, Sramek, Vladimir, Zaric, Bojan, Yamamiya, Ikuo, Benhadji, Karim A., Hamada, Kensuke, He, Yaohua, Rosen, Lee

“…Purpose Trifluridine/tipiracil (FTD/TPI) is approved for advanced colorectal and gastric/gastroesophageal cancer; however, data in patients with renal…”
Get full text

Efficacy of sequential treatment of HCT116 colon cancer monolayers and xenografts with docetaxel, flavopiridol, and 5-fluorouracil by Guo, Jun, Zhou, An-wu, Fu, Yu-cai, Verma, Udit N, Tripathy, Debu, Frenkel, Eugene P, Becerra, Carlos R

“…Aim： Clinical treatment of solid tumors with docetaxel, flavopiridol, or 5-fluorouracil （5-FU） often encounters undesirable side effects and drug resistance…”
Get full text

A Phase 1, Open‐Label, Randomized, Crossover Study Evaluating the Bioavailability of TAS‐102 (Trifluridine/Tipiracil) Tablets Relative to an Oral Solution Containing Equivalent Amounts of Trifluridine and Tipiracil by Becerra, Carlos R., Yoshida, Kenichiro, Mizuguchi, Hirokazu, Patel, Manish, Hoff, Daniel

“…TAS‐102 (trifluridine/tipiracil) is composed of an antineoplastic thymidine‐based nucleoside analogue trifluridine (FTD), and a thymidine phosphorylase…”
Get full text

Author Correction: Targeting LIF-mediated paracrine interaction for pancreatic cancer therapy and monitoring by Shi, Yu, Gao, Weina, Lytle, Nikki K., Huang, Peiwu, Yuan, Xiao, Dann, Amanda M., Ridinger-Saison, Maya, DelGiorno, Kathleen E., Antal, Corina E., Liang, Gaoyang, Atkins, Annette R., Erikson, Galina, Sun, Huaiyu, Meisenhelder, Jill, Terenziani, Elena, Woo, Gyunghwi, Fang, Linjing, Santisakultarm, Thom P., Manor, Uri, Xu, Ruilian, Becerra, Carlos R., Borazanci, Erkut, Von Hoff, Daniel D., Grandgenett, Paul M., Hollingsworth, Michael A., Leblanc, Mathias, Umetsu, Sarah E., Collisson, Eric A., Scadeng, Miriam, Lowy, Andrew M., Donahue, Timothy R., Reya, Tannishtha, Downes, Michael, Evans, Ronald M., Wahl, Geoffrey M., Pawson, Tony, Tian, Ruijun, Hunter, Tony

Get full text

A phase II study with cetuximab and radiation therapy for patients with surgically resectable esophageal and GE junction carcinomas: Hoosier Oncology Group G05-92 by Becerra, Carlos R, Hanna, Nasser, McCollum, Andrew David, Becharm, Naftali, Timmerman, Robert D, DiMaio, Michael, Kesler, Kenneth A, Yu, Menggang, Yan, Tong, Choy, Hak

“…On the basis of the promising activity of cetuximab and radiation therapy for head and neck cancers, we evaluated the efficacy of this regimen followed by…”
Get more information

Phase 2 trial of afatinib, an ErbB family blocker, in solid tumors genetically screened for target activation by Kwak, Eunice L., Shapiro, Geoffrey I., Cohen, Seth M., Becerra, Carlos R., Lenz, Heinz‐Josef, Cheng, Wen‐Fang, Su, Wu-Chou, Robohn, Meghan, Le Maulf, Florence, Lobmeyer, Maximilian T., Chand, Vikram K., Iafrate, A. John

“…BACKGROUND The efficacy of afatinib, an irreversible ErbB Family Blocker, was evaluated in patients who had 1 of 4 categories of solid tumors with epidermal…”
Get full text

Figitumumab in patients with refractory metastatic colorectal cancer previously treated with standard therapies: a nonrandomized, open-label, phase II trial by Becerra, Carlos R., Salazar, Ramon, Garcia-Carbonero, Rocio, Thomas, Anne L., Vázquez-Mazón, Federico J., Cassidy, James, Maughan, Tim, Castillo, Manuel Gallén, Iveson, Tim, Yin, Donghua, Green, Stephanie, Bergsland, Emily K.

“…Purpose Figitumumab (CP-751,871) is a human IgG2 monoclonal antibody that binds and down-regulates insulin-like growth factor receptor-1 (IGF-1R) and inhibits…”
Get full text

A phase I dose-escalation study of MEDI-575, a PDGFRα monoclonal antibody, in adults with advanced solid tumors by Becerra, Carlos R., Conkling, Paul, Vogelzang, Nicholas, Wu, Hilary, Hong, Shengyan, Narwal, Rajesh, Liang, Meina, Tavakkoli, Fatemeh, Pandya, Naimish

“…Purpose The purpose of the study was to evaluate safety and determine the maximum tolerated dose (MTD) of MEDI-575, a fully human monoclonal antibody that…”
Get full text

Locally advanced carcinosarcoma of the pancreas by Still, Sasha A, Becerra, Carlos R, Clement-Kruzel, Stacia E, Cavaness, Keith M

“…Carcinosarcoma is a rare subtype of pancreatic neoplasm including both carcinomatous and sarcomatous components. Fewer than 30 cases have been reported to the…”
Get full text

An innovative, multi-arm, complete phase 1b study of the novel anti-cancer agent tasisulam in patients with advanced solid tumors by Jotte, Robert M., Von Hoff, Daniel D., Braiteh, Fadi, Becerra, Carlos R., Richards, Donald A., Smith, David A., Garbo, Lawrence, Stephenson, Joe, Conkling, Paul R., Robert-Vizcarrondo, Francisco, Chen, Jian, Turner, P. Kellie, Chow, Kay Hoong, Tai, D. Fritz, Ilaria, Robert

“…Summary Background This phase Ib study used a parallel, multi-arm design to examine tasisulam-sodium (hereafter tasisulam), a drug with complex pharmacology,…”
Get full text

IκB Kinase α Regulates Subcellular Distribution and Turnover of Cyclin D1 by Phosphorylation by Kwak, Youn-Tae, Li, Rui, Becerra, Carlos R., Tripathy, Debu, Frenkel, Eugene P., Verma, Udit N.

“…IκB kinases (IKKs), IKKα and IKKβ, with a regulatory subunit IKKγ/NEMO constitute a high molecular weight IKK complex that regulates NF-κB activity. Although…”
Get full text

Increased toxicity and lack of efficacy of Rofecoxib in combination with chemotherapy for treatment of metastatic colorectal cancer: A phase II study by Becerra, Carlos R., Frenkel, Eugene P., Ashfaq, Raheela, Gaynor, Richard B.

“…Preclinical and clinical models have demonstrated that cyclooxygenase‐2 (COX‐2) is overexpressed in primary and metastatic colorectal tumors. In preclinical…”
Get full text

A Phase I Study of the Safety, Pharmacokinetics, and Pharmacodynamics of Combination Therapy with Refametinib plus Sorafenib in Patients with Advanced Cancer by Adjei, Alex A, Richards, Donald A, El-Khoueiry, Anthony, Braiteh, Fadi, Becerra, Carlos H R, Stephenson, Jr, Joe J, Hezel, Aram F, Sherman, Morris, Garbo, Lawrence, Leffingwell, Diane P, Iverson, Cory, Miner, Jeffrey N, Shen, Zancong, Yeh, Li-Tain, Gunawan, Sonny, Wilson, David M, Manhard, Kimberly J, Rajagopalan, Prabhu, Krissel, Heiko, Clendeninn, Neil J

“…To assess the safety and tolerability of the small-molecule allosteric MEK inhibitor refametinib combined with sorafenib, in patients with advanced solid…”
Get full text

Irinotecan, epirubicin, and capecitabine in metastatic adenocarcinomas: preliminary results of a phase I study by Becerra, Carlos R

“…The combination of irinotecan (Camptosar), epirubicin, and capecitabine (Xeloda) has shown an acceptable toxicity profile. In this open-label phase I study,…”
Get more information

A Phase I Single-Dose Trial of Gadolinium Texaphyrin (Gd-Tex), a Tumor Selective Radiation Sensitizer Detectable by Magnetic Resonance Imaging by ROSENTHAL, D. I, NURENBERG, P, RENSCHLER, M. F, BECERRA, C. R, FRENKEL, E. P, CARBONE, D. P, LUM, B. L, MILLER, R, ENGEL, J, YOUNG, S, MILES, D

“…Gadolinium Texaphyrin (Gd-Tex) is a radiation sensitizer with a novel mechanism of action that sensitizes both oxic and hypoxic cells, localizes selectively in…”
Get full text